Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-111 in recurrent glioblastoma
NCT04406272Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2020
- Primary completion
- Aug 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of ofranergene obadenovec in glioblastoma (GBM), sponsored by Dana-Farber Cancer Institute. Started Aug 2020; status: terminated.
02
Drugs
ofranergene obadenovec
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04406272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406272.